top of page

ENHERTU - Discover a new indication & how it may help certain patients with unmet needs ~ March 4th

Feb 17, 20211 min read

Indication

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.

Recent Posts

See All

NEW EVENT! Make a Change in cGVHD Treatment Strategy and Provide Rapid, Durable Responses ~ March 19th, 2025 at Joe's on Newbury

RI & SE Mass ONS Chapter Spring Conference ~ March 22nd!

Career Fair ~ Wednesday, January 29th! This week 12-1pm EST

Comments

bottom of page